Future work should assess the merits and disadvantages of the various PDGFRB-targeting platforms (affibody, nanobody, small molecule, etc.)in terms of pharmacokinetics, binding affinities and specificities, and tumour tissue retention. The gene discussed is PDGFRB; the disease is neoplasm.